Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Solid Biosciences Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

CHARLESTOWN, MASS., OCT. 01, 2025 (GLOBE NEWSWIRE) -- SOLID BIOSCIENCES INC. (NASDAQ: SLDB) (THE COMPANY), A LIFE SCIENCES COMPANY DEVELOPING PRECISION GENETIC MEDICINES FOR NEUROMUSCULAR AND CARDIAC DISEASES, TODAY ANNOUNCED GRANTS OF 116,150 RESTRICTED STOCK UNITS (RSUS) TO FOUR NEWLY HIRED EMPLOYEES.

SOLID BIOSCIENCES REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

CHARLESTOWN, MASS., OCT. 01, 2025 (GLOBE NEWSWIRE) -- SOLID BIOSCIENCES INC. (NASDAQ: SLDB), A LIFE SCIENCES COMPANY DEVELOPING PRECISION GENETIC MEDICINES FOR NEUROMUSCULAR AND CARDIAC DISEASES, WILL PRESENT DATA FROM ITS NEUROMUSCULAR AND CARDIAC PROGRAMS AT THE WORLD MUSCLE SOCIETY (WMS) 2025 ANNUAL INTERNATIONAL CONGRESS, OCTOBER 7-11, 2025, IN VIENNA, AUSTRIA, AND AT THE EUROPEAN SOCIETY OF GENE & CELL THERAPY (ESGCT) 2025 ANNUAL CONGRESS, OCTOBER 7-12, 2025, IN SEVILLE, SPAIN.

SOLID BIOSCIENCES TO PRESENT AT UPCOMING SCIENTIFIC MEETINGS

CHARLESTOWN, MASS., SEPT. 25, 2025 (GLOBE NEWSWIRE) -- SOLID BIOSCIENCES INC. (NASDAQ: SLDB), A LIFE SCIENCES COMPANY DEVELOPING PRECISION GENETIC MEDICINES FOR NEUROMUSCULAR AND CARDIAC DISEASES, WILL PRESENT DATA FROM THE PHASE 1/2 INSPIRE DUCHENNE TRIAL EVALUATING SGT-003, A NEXT-GENERATION INVESTIGATIONAL GENE THERAPY INTENDED FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DUCHENNE), AT THE 26TH ANNUAL SCIENTIFIC MEETING OF NEUROMUSCULAR STUDY GROUP (NMSG), SEPTEMBER 26-28, 2025, IN STRESA, ITALY. PRESENTATIONS WILL INCLUDE PREVIOUSLY REPORTED DAY 90 BIOPSY DATA IN ADDITION TO UPDATED SAFETY DATA AS OF THE AUGUST 12, 2025, DATA CUTOFF FROM THE INSPIRE DUCHENNE TRIAL.

SOLID BIOSCIENCES TO PRESENT AT 2025 NEUROMUSCULAR STUDY GROUP ANNUAL SCIENTIFIC MEETING

- NON-EXCLUSIVE LICENSE FOR SOLID'S PROPRIETARY, NEXT GENERATION CAPSID, AAV-SLB101, TO ACCELERATE DEVELOPMENT OF KINEA BIO'S GENE THERAPY FOR DYSFERLIN-RELATED LIMB-GIRDLE MUSCULAR DYSTROPHY -

SOLID BIOSCIENCES ANNOUNCES LICENSING AGREEMENT WITH KINEA BIO FOR THE USE OF PROPRIETARY NEXT-GENERATION CAPSID AAV-SLB101

SEATTLE--(BUSINESS WIRE)--KINEA BIO INC., A BIOTECHNOLOGY COMPANY DEDICATED TO DEVELOPING TRANSFORMATIVE GENETIC MEDICINES, TODAY ANNOUNCED TWO MAJOR ACHIEVEMENTS IN ITS GENE THERAPY PROGRAM: A COMMITMENT BY THE JAIN FOUNDATION TO INVEST UP TO $1.1 MILLION BASED ON THE ACHIEVEMENT OF CERTAIN MILESTONES TO SUPPORT CRITICAL PRECLINICAL STUDIES, AND A STRATEGIC LICENSE FROM SOLID BIOSCIENCES FOR ITS PROPRIETARY, NEXT-GENERATION MYOTROPIC AAV CAPSID, AAV-SLB101, TO ENABLE SAFE AND EFFECTIVE MUSCLE-.

KINEA BIO SECURES $1.1M JAIN FOUNDATION INVESTMENT AND SOLID BIOSCIENCES CAPSID LICENSE TO ADVANCE NOVEL GENE THERAPY FOR DYSFERLINOPATHY, A RARE NEUROMUSCULAR DISEASE

CHARLESTOWN, MASS., AUG. 28, 2025 (GLOBE NEWSWIRE) -- SOLID BIOSCIENCES INC. (NASDAQ: SLDB) (THE COMPANY OR SOLID), A LIFE SCIENCES COMPANY DEVELOPING PRECISION GENETIC MEDICINES FOR NEUROMUSCULAR AND CARDIAC DISEASES, TODAY ANNOUNCED PARTICIPATION IN THE FOLLOWING INVESTOR CONFERENCES:

SOLID BIOSCIENCES TO PARTICIPATE AT UPCOMING INVESTOR CONFERENCES

- DUCHENNE (SGT-003): 15 PARTICIPANTS DOSED IN THE PHASE 1/2 INSPIRE DUCHENNE TRIAL AND DOSING REMAINS ONGOING; ON TRACK TO DISCUSS REGULATORY PATHWAYS WITH U.S. FDA IN Q4 2025 -

SOLID BIOSCIENCES REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

CHARLESTOWN, MASS., AUG. 01, 2025 (GLOBE NEWSWIRE) -- SOLID BIOSCIENCES INC.(NASDAQ: SLDB) (THE COMPANY), A LIFE SCIENCES COMPANY DEVELOPING PRECISION GENETIC MEDICINES FOR NEUROMUSCULAR AND CARDIAC DISEASES, TODAY ANNOUNCED GRANTS OF 55,450 RESTRICTED STOCK UNITS (RSUS) TO FOUR NEWLY HIRED EMPLOYEES.

- SGT-501 HAS NOW RECEIVED FDA FAST TRACK, ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS - - POTENTIAL FIRST-IN-CLASS THERAPY WITH FDA IND CLEARANCE AND HEALTH CANADA CTA APPROVAL DESIGNED TO ADDRESS UNDERLYING CAUSES OF CPVT, A LIFE-THREATENING, ARRHYTHMOGENIC CARDIAC CONDITION - - SOLID EXPECTS TO INITIATE PHASE 1B CLINICAL TRIAL OF SGT-501 IN THE FOURTH QUARTER OF 2025 - CHARLESTOWN, MASS., JULY 23, 2025 (GLOBE NEWSWIRE) -- SOLID BIOSCIENCES INC. (NASDAQ: SLDB), A CLINICAL STAGE LIFE SCIENCES COMPANY DEVELOPING PRECISION GENETIC MEDICINES FOR NEUROMUSCULAR AND CARDIAC DISEASES, TODAY ANNOUNCED THAT IT RECEIVED FAST TRACK DESIGNATION FROM THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR SGT-501, THE COMPANY'S NOVEL, AAV-BASED INVESTIGATIONAL GENE THERAPY FOR THE TREATMENT OF CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA (CPVT).

SOLID BIOSCIENCES RECEIVES FDA FAST TRACK DESIGNATION FOR SGT-501 FIRST-IN-CLASS GENE THERAPY FOR CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA (CPVT)

- SGT-501 IS A NOVEL GENE THERAPY FOR RARE, LIFE-THREATENING, GENETIC ARRHYTHMOGENIC DISEASE WITH NO APPROVED THERAPIES - - SGT-501 HAS RECEIVED ORPHAN DRUG DESIGNATION AND RARE PEDIATRIC DISEASE DESIGNATION FROM THE FDA - - SOLID EXPECTS TO INITIATE PHASE 1B CLINICAL TRIAL OF SGT-501 IN THE FOURTH QUARTER OF 2025 - - EXPANDS SOLID'S CLINICAL PIPELINE TO INCLUDE FIRST CARDIAC INDICATION WITH URGENT UNMET MEDICAL NEED - CHARLESTOWN, MASS., JULY 08, 2025 (GLOBE NEWSWIRE) -- SOLID BIOSCIENCES INC. (NASDAQ: SLDB) (THE COMPANY OR SOLID), A LIFE SCIENCES COMPANY DEVELOPING PRECISION GENETIC MEDICINES FOR NEUROMUSCULAR AND CARDIAC DISEASES, TODAY ANNOUNCED APPROVAL OF ITS INVESTIGATIONAL NEW DRUG (IND) APPLICATION BY THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) AND CLINICAL TRIAL APPLICATION (CTA) BY HEALTH CANADA FOR SGT-501, A NOVEL GENE THERAPY APPROACH FOR THE TREATMENT OF CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA (CPVT), A HIGHLY MALIGNANT, ARRHYTHMOGENIC CHANNELOPATHY CAUSED BY GENETIC MUTATIONS THAT IMPACT THE RYANODINE RECEPTOR (RYR2) IN CARDIAC MUSCLE.

SOLID BIOSCIENCES ANNOUNCES FDA IND AND HEALTH CANADA CTA APPROVAL FOR FIRST-IN-CLASS CARDIAC GENE THERAPY TO TREAT CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA (CPVT)

Solid Biosciences Inc.

SLDB

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Solid Biosciences Inc.

SLDB.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

SLDB